

Relative IL-11 release post TGF-β pulse
125
100
75
50
25
0
TGF-β1
TGF-β2
TGF-β3
10-3 10-2 10-1 100 101 102 103 104 105 106
Concentration (pM)

FIG. 1



1-month GLP toxicology study (NHP): I.V., up to 30 mg/kg
Day 1 15 29 31 57
TGF-β Ligand Trap (or vehicle)
Follow-up
6-month GLP toxicology study (NHP): subcut., up to 25 mg/kg
Day 1 8 15 22 29 36 43 50 57 64 155 162 169 176 183 +1
(27 doses total)
TGF-β Ligand Trap (or vehicle)
QIW for 6 months

FIG. 2



Monkey serum at before and after TGFb ligand trap administration
acid activation to release all endogenous serum TGF-β1, β2 & β3.
TGF-β Ligand Trap in serum traps TGF-β1 and -β3
TGF-β1
TGF-β1
ELISA

FIG. 3



A
PK Profile
Concentration (ng/mL)
1000000
100000
10000
1000
100
0
7
14
21
Time (days post-SOI)
B
Target Engagement
TGF-β1 concentration (pg/mL)
80000
60000
40000
20000
0
Pre-Tx
3
21
Time (Days post-EOI)

FIG. 4

FIG. 5A




FIG. 5B




FIG. 5C





FIG. 5D





1200
1000
800
600
400
200
0
Tumor volume (mm3)
IgG
Anti-PD-L1
TGF-β Ligand Trap
Anti-PD-L1 +
TGF-β Ligand Trap
0
5
10
15
Days

FIG. 6